|
|
|
|
Pneumatic Compression Devices Are an Effective Therapy for Restless Legs Syndrome: A Prospective, Randomized,
IntroductionPharmacotherapy for restless legs syndrome may be ineffective or complicated by side effects.Uncontrolled series using pneumatic compression devices have been shown to reduce symptoms of restless legs syndrome.
|
|
|
Making SALSA: How Two Chefs in a 'Kitchen' Can Save Legs and Lives
The Southern Arizona Limb Salvage Alliance (SALSA) uses a multidisciplinary team approach to wound healing and prevention of amputations in people with diabetes.In August, David G. Armstrong, DPM, PhD, a renowned podiatrist and...
|
|
|
GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzira(T
RESEARCH TRIANGLE PARK, N.C.& SANTA CLARA, Calif.--(BUSINESS WIRE)--November 10, 2008--GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced today that the New Drug Application (NDA) for Solzira (gabapentin...
|
|
|
GSK and Xenoport announce plans to withdraw and resubmit new drug application requesting approval of Solzira
e plans to withdraw and resubmit new drug application requesting approval of Solzira for restless legs syndrome GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc.(Nasdaq: XNPT) announced today that the New Drug Application (NDA) for...
|
|
|
GSK and Xenoport announce plans to withdraw and resubmit new drug application requesting approval of Solzira f
GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc.announced that the New Drug Application (NDA) for Solzira (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome ...
|
|
|
GSK to withdraw, resubmit RLS drug approval
GlaxoSmithKline and its partner XenoPort have withdrawn their NDA approval application for Restless Leg Syndrome drug and plan to resubmit it.GSK had submitted a New Drug Application (NDA) for Solzira (gabapentin enacarbil) Extended...
|
|
|
11 Nov 08 | GSK and Xenoport announce plans to withdraw and resubmit new drug application requesting approval
e plans to withdraw and resubmit new drug application requesting approval of Solzira for restless legs syndrome GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc.(Nasdaq: XNPT) announced today that the New Drug Application (NDA) for...
|
|
|
::: GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzi
RESEARCH TRIANGLE PARK, N.C.& SANTA CLARA, Calif.--(BUSINESS WIRE)--GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced today that the New Drug Application (NDA) for Solzira (gabapentin enacarbil) Extended Release...
|
|
|
GSK and Xenoport withdraw NDA for Solzira
GlaxoSmithKline and Xenoport have announced that the new drug application for Solzira or Gabapentin Enacarbil extended release tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome or RLS has been...
|
|
|
XenoPort Dips In Pre-Market On Withdrawl Of NDA For Primary Restless Legs Syndrome Drug
XenoPort (XNPT: News ) slid in pre-market trading, after withdrawing with GlaxoSmithKline (GSK: News ) their NDA for Solzira extended release tablets for primary restless legs syndrome.The stock was down $5.57 just after 9:00 am ET,...
|
|
|
GlaxoSmithKline and Xenoport withdraw NDA for Solzira for Restless Legs Syndrome - Update
GlaxoSmithKline (GSK: News ) and Xenoport, Inc.(XNPT: News ) announced on Monday that the New Drug Application or NDA for Solzira or gabapentin enacarbil extended release tablets for the treatment of moderate-to-severe primary Restless...
|
|
|
UPDATE: Glaxo, XenoPort Withdraw Restless Legs Syndrome Drug App
By Benjamin Pimentel SAN FRANCISCO (Dow Jones) -- GlaxoSmithKline and XenoPort Inc.announced Monday the withdrawal of an application for approval by the Food and Drug Administration of a drug for restless legs syndrome. Glaxo (GSK...
|
|
|
UPDATE: Glaxo, XenoPort Withdraw Restless Legs Syndrome Drug App
SAN FRANCISCO (Dow Jones) -- GlaxoSmithKline and XenoPort Inc.announced Monday the withdrawal of an application for approval by the Food and Drug Administration of a drug for restless legs syndrome. Glaxo (GSK) said it plans to...
|
|
|
Glaxo, XenoPort Pull Restless Legs Syndrome Drug Application
By Benjamin Pimentel GlaxoSmithKline PLC (GSK) and XenoPort Inc.(XNPT) announced Monday the withdrawal of an application for approval by the Food and Drug Administration of a drug for restless legs syndrome. Glaxo said it plans to...
|
|
|
GSK to withdraw, resubmit RLS app
GlaxoSmithKline and XenoPort have withdrawn their NDA for Solzira, a treatment for moderate-to-severe primary Restless Legs Syndrome.The FDA wants data in a single study to be reformatted, and GSK will conduct a review of...
|
|
|
GSK, XenoPort Will Resubmit Solzira NDA
GlaxoSmithKline and XenoPort, Inc.withdrew the NDA for Solzira Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). The FDA has requested that the data in a single study be...
|
|
|
UPDATE: Glaxo, XenoPort Withdraw Restless Legs Syndrome Drug App
SAN FRANCISCO XenoPort The companies said the withdrawal of the application 'does not relate to the content of the filing.' They said the FDA asked that 'the data in a single study be reformatted.UPDATE: Glaxo, XenoPort Withdraw ...
|
|
|
GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzira f
RESEARCH TRIANGLE PARK, N.C.& SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov 10, 2008 - GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced today that the New Drug Application (NDA) for Solzira(TM) (gabapentin enacarbil...
|
|
|
Glaxo (GSK) and XenoPort's (XNPT) NDA for Solzira(TM) Withdrawn
GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc.(Nasdaq: XNPT) announced today that the New Drug Application for Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless ...
|
|
|
GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzira f
RESEARCH TRIANGLE PARK, N.C.& SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov 10, 2008 - GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced today that the New Drug Application (NDA) for Solzira(TM) (gabapentin...
|
|
|
GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzira(T
RESEARCH TRIANGLE PARK, N.C.& SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov 10, 2008 - GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced today that the New Drug Application (NDA) for Solzira(TM) (gabapentin enacarbil...
|
|
|
GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzira(T
Business Editors/Health/Medical Writers RESEARCH TRIANGLE PARK, N.C.& SANTA CLARA, Calif.--(BUSINESS WIRE)--November 10, 2008--GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced today that the New Drug Application...
|
|
|
Neurogen Corporation Announces Third Quarter 2008 Financial Results and Updates Operations
Neurogen Corporation (Nasdaq: NRGN), a drug development company focused on improved drugs for psychiatric and neurological disorders, today announced financial and operational results for the three and nine month periods ended September 30,...
|
|
|
Neurogen Corporation Announces Third Quarter 2008 Financial Results and Updates Operations
-Neurogen Corporation (Nasdaq: NRGN), a drug development company focused on improved drugs for psychiatric and neurological disorders, today announced financial and operational results for the three and nine month periods ended September 30,...
|
|
|
Cardiovascular Systems, Inc
Replidyne, Inc.(RDYN) to Be Bought by Private Medical Device Maker, 11/4/2008 6:51:11 AM More...Cardiovascular Systems, Inc.Files for $86 Million IPO 1/23/2008 7:23:07 AM More... Cardiovascular Systems, Inc.'s New Device for Clearing...
|
